REPLIGEN CORP Debt Securities, Available-for-sale, Amortized Cost
REPLIGEN CORP (RGEN) had Debt Securities, Available-for-sale, Amortized Cost of $203.79 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-29
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $203.79M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $201.94M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $201.55M.
- 2013-12-31: Debt Securities, Available-for-sale, Amortized Cost $34.02M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $203.79M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $201.94M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $201.55M 10-Q · filed 2026-07-29 |
| 2013-12-31 | $34.02M 10-K · filed 2014-03-14 |
| 2013-09-30 | $24.85M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $25.45M 10-Q · filed 2013-08-07 |
| 2013-03-31 | $25.47M 10-Q · filed 2013-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |